• Royalty Pharma on IP-diligence in its US$2.025 billion strategic funding partnership as part of MorphoSys' US$1.7 billion acquisition of Constellation Pharmaceuticals. 

    • Royalty Pharma in its US$342 million acquisition of the royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK).

    • Royalty Pharma in its acquisition of royalty interest in Seltorexant from Minerva Neuroscience.

    • Royalty Pharma in its US$575 million acquisition of the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis treatments owned by the Cystic Fibrosis Foundation.

    • Royalty Pharma in its US$650 million royalty purchase agreement with PTC Therapeutics, Inc. to acquire a portion of PTC’s royalty interest in Risdiplam.

    • Royalty Pharma in its US$255 million acquisition from Agios Pharmaceuticals, Inc., of sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA® (enasidenib).

    • Royalty Pharma in its US$220 million acquisition of AiCuris Anti-infective Cures GmbH’s partial royalty interest in Prevymis™ (letermovir).

    • Royalty Pharma in its US$94 million acquisition of Massachusetts General Hospital’s royalty interest in Entyvio (vedolizumab).

    • Royalty Pharma in its US$330 million acquisition of Eisai Co., Ltd.’s royalties on sales of Epizyme Inc.’s soon-to-be-FDA-approved drug tazemetostat.

    • Royalty Pharma in its US$100 million equity investment (with options to invest up to an additional US$100 million) in Epizyme Inc. 

    • Royalty Pharma in its US$827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta.
    • Carnegie Mellon University, B.S., Chemistry, Economics and Business, 1998, Highest Honors, Phi Beta Kappa, Mellon Scholarship in Science, NASA Undergraduate Research Fellowship
    • Carnegie Mellon University, M.S., Physical Organic Chemistry, 1999
    • Harvard University, A.M., Organic Chemistry, 2001, Hoffman-La Roche Fellowship in Organic Chemistry, GEM Graduate Fellowship
    • Harvard University, Ph.D., Synthetic Organic Chemistry, 2004, National Science Foundation Pre-Doctoral Fellow, The Christensen Prize for Outstanding Research Achievement, Derek C. Bok Award for Excellence in Teaching
    • New York University, J.D., 2009, Intellectual Property Law Scholar
    • New York
    • Massachusetts
    • United States District Court for the Southern District of New York
    • United States Patent and Trademark Office
    • United States District Court for the Eastern District of New York
    • American Bar Association
    • American Intellectual Property Law Association
    • New York State Bar Association
    • American Chemical Society
    • Original Sin: How Origination Credit Is a Barrier to Diversity Goals — Virtual (October 20, 2020)

      Speaker, Hosted by the Office for Diversity & Inclusion of the New York City Bar Association.
    • China Pharma IP Summit 2019 — Shanghai, China (October 23-25, 2019)

      Speaker, "Keys to Maximizing U.S. Patent Term.”
    • Managing Intellectual Property US Patent Forum 2019 — New York, NY (April 3-4, 2019)

      Speaker, “Counteracting the flux of patent eligibility” panel. Topics include: Tracking the evolution of subject matter eligibility in the US, Consequences of Alice for patent owners: new section 101 guidance?, Meeting the demands of new technologies, and Integrating open-source and patents. For more information, visit the event page
    • Identifying Patent Examiner Biases and Making Them Work Using Legal Analytics — Legal Analytics and the Business of Law Summit, New York (November 18, 2014)

      Speaker, panel discussing the use of predictive analytics to identify and overcome examiner biases to improve outcomes, increase speed, and create client value.